A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Obesity

Treatments: Drug: BI 456906; Drug: Placebo for BI 1820237; Drug: Placebo for BI 456906; Drug: BI 1820237

Study type: Interventional

Funder types: Industry

Identifiers

NCT06352424

2023-506233-30-01 (Registry Identifier)

U1111-1293-4672 (Registry Identifier)

1458-0006

Details and patient eligibility

About

The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.

Enrollment: 23 patients

Sex: All

Ages: 40 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female subjects with obesity/overweight (otherwise healthy) according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs (Blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests

2. Age of 40 to 60 years (inclusive)

3. Body mass index (BMI) of 27.0 to 40.0 kg/m2 (inclusive). Overweight/obesity should be due to excess adipose tissue, as judged by the Investigator

4. Body weight greater than or equal to 75 kg

5. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

6. Male trial participants without need for contraception

7. Female trial participants, only if any of the following criteria for a highly effective contraception from at least 30 days before the first administration of trial medication until 2 months after last administration of trial medication are met:

   • Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (intravaginal or transdermal)
   • Bilateral tubal occlusion
   • A vasectomised sexual partner who received medical assessment of the surgical success (documented absence of sperm according to verbal confirmation of female participant) and provided that partner is the sole sexual partner of the trial participant
   • Abstention from male-female sex. This is defined as being in line with the preferred and usual lifestyle of the patient. Periodic abstinence e.g. calendar, ovulation, symptothermal, post-ovulation methods; declaration of abstinence for the duration of exposure to study drug, and withdrawal are not acceptable.

Or female subject meets any of the following criteria:

• Permanent sterilisation by hysterectomy, bilateral salpingectomy and/or bilateral oophorectomy
• Woman is postmenopausal, defined as no menses for 1 year without an alternative medical cause (in questionable cases a blood sample with follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion criteria

1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator
2. Measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm and assessed as clinically relevant by the investigator
3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
4. Any evidence of a concomitant disease
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

23 participants in 4 patient groups

A-B-C-D

Experimental group

Description:

* A: Treatment Test 1 (T1): BI 1820237 + Placebo for BI 456906 * B: Treatment Test 2 (T2): BI 456906 + Placebo for BI 1820237 * C: Treatment Test 3 (T3): BI 1820237 + BI 456906 * D: Treatment Reference (R1, R2): Placebo for BI 1820237 + Placebo for BI 456906

Treatment:

Drug: BI 1820237

Drug: Placebo for BI 456906

Drug: Placebo for BI 1820237

Drug: BI 456906

B-D-A-C

Experimental group

Treatment:

Drug: BI 1820237

Drug: Placebo for BI 456906

Drug: Placebo for BI 1820237

Drug: BI 456906

C-A-D-B

Experimental group

Treatment:

Drug: BI 1820237

Drug: Placebo for BI 456906

Drug: Placebo for BI 1820237

Drug: BI 456906

D-C-B-A

Experimental group

Treatment:

Drug: BI 1820237

Drug: Placebo for BI 456906

Drug: Placebo for BI 1820237

Drug: BI 456906